These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7981460)

  • 1. Droloxifene, a new antiestrogen: its role in metastatic breast cancer.
    Rauschning W; Pritchard KI
    Breast Cancer Res Treat; 1994; 31(1):83-94. PubMed ID: 7981460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical data for Droloxifene.
    Hasmann M; Rattel B; Löser R
    Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
    Buzdar A; Hayes D; El-Khoudary A; Yan S; Lønning P; Lichinitser M; Gopal R; Falkson G; Pritchard K; Lipton A; Wolter K; Lee A; Fly K; Chew R; Alderdice M; Burke K; Eisenber P;
    Breast Cancer Res Treat; 2002 May; 73(2):161-75. PubMed ID: 12088118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of advanced breast cancer in postmenopausal women with droloxifene: results of a double-blind phase II trial for dose determination].
    Chevallier B; Spielmann M; Marty M; Serin D; Pouillart P; Tubiana Hulin M; Mignot L; Pujade Lauraine E; Krams M; Mertens H
    Bull Cancer; 1993 Jul; 80(7):624-8. PubMed ID: 8204943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group.
    Deschênes L
    Am J Clin Oncol; 1991; 14 Suppl 2():S52-5. PubMed ID: 1962599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic and biologic properties of droloxifene, a new antiestrogen.
    Eppenberger U; Wosikowski K; Küng W
    Am J Clin Oncol; 1991; 14 Suppl 2():S5-14. PubMed ID: 1962598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
    Geisler J; Ekse D; Hösch S; Lønning PE
    J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of droloxifene in patients with metastatic breast cancer.
    Buzdar AU; Kau S; Hortobagyi GN; Theriault RL; Booser D; Holmes FA; Walters R; Krakoff IH
    Cancer Chemother Pharmacol; 1994; 33(4):313-6. PubMed ID: 8281625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients.
    Kvinnsland S
    Am J Clin Oncol; 1991; 14 Suppl 2():S46-51. PubMed ID: 1962597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese early phase II study of droloxifene in the treatment of advanced breast cancer. Preliminary dose-finding study.
    Abe O
    Am J Clin Oncol; 1991; 14 Suppl 2():S40-5. PubMed ID: 1962596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid hormone levels in patients with advanced breast cancer during therapy with droloxifene: a pilot study.
    Dalski J; Görlich M
    Tumori; 1996; 82(1):45-7. PubMed ID: 8623503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine management of breast cancer.
    Schneider PG; Jackisch C; Brandt B
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer.
    Geisler J; Haarstad H; Gundersen S; Raabe N; Kvinnsland S; Lønning PE
    J Endocrinol; 1995 Aug; 146(2):359-63. PubMed ID: 7561649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells.
    Knabbe C; Zugmaier G; Schmahl M; Dietel M; Lippman ME; Dickson RB
    Am J Clin Oncol; 1991; 14 Suppl 2():S15-20. PubMed ID: 1835818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment.
    Haarstad H; Lønning PE; Gundersen S; Wist E; Raabe N; Kvinnsland S
    Acta Oncol; 1998; 37(4):365-8. PubMed ID: 9743458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.
    Arpino G; Nair Krishnan M; Doval Dinesh C; Bardou VJ; Clark GM; Elledge RM
    Ann Oncol; 2003 Feb; 14(2):233-41. PubMed ID: 12562650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of toremifene in breast cancer patients. A phase II study.
    Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Nordman E; Taskinen P; Holsti LR; Hajba A
    J Steroid Biochem; 1990 Jun; 36(3):229-31. PubMed ID: 2142240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternate antiestrogens and approaches to the prevention of breast cancer.
    Jordan VC
    J Cell Biochem Suppl; 1995; 22():51-7. PubMed ID: 8538210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial.
    Bruning PF
    Eur J Cancer; 1992; 28A(8-9):1404-7. PubMed ID: 1515258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.